

Supplementary Appendix for ‘Anti-SARS-CoV2 antibody responses are impaired in patients with inflammatory bowel disease treated with infliximab’

Table of Contents

Supplementary Table S1: Contributors to the CLARITY IBD study	2
Supplementary Table S2: Baseline characteristics stratified by baseline characteristics after propensity matching by inflammatory bowel disease (IBD) subtype, immunomodulator use, cancer, age, active IBD and comorbidities	18
Supplementary Figure S1: Regional seroprevalence of SARS-CoV-2 by NUTS1 region	19
Supplementary Figure S2: Magnitude of antibody reactivity to SARS-CoV-2 in participants who had a positive PCR to SARS-CoV-2 at least two weeks earlier and positive anti-SARS-CoV-2 serology (≥ 1 COI), stratified by choice of biologic	20
Supplementary Figure S3: Magnitude of antibody reactivity to SARS-CoV-2 in participants treated with infliximab who had a positive PCR to SARS-CoV-2 at least two weeks earlier, stratified by immunomodulator use	21

Supplementary Appendix for 'Anti-SARS-CoV2 antibody responses are impaired in patients with inflammatory bowel disease treated with infliximab'

Supplementary Table S1: Contributors to the CLARITY IBD study

Affiliation	First name	Surname
Barts Health NHS Trust	Klaartje	Kok
	Farjhana	Bokth
	Bessie	Cipriano
	Caroline	Francia
	Nosheen	Khalid
	Hafiza	Khatun
	Ashley	Kingston
	Irish	Lee
	Anouk	Lehmann
	Kinnari	Naik
	Elise	Pabriaga
	Nicolene	Plaatjies
	Kevin	Samuels
Barts Health NHS Trust (paediatric)	Bessie	Cipriano
	Kevin	Samuels
	Nicolene	Plaatjies
	Hafiza	Khatun
	Farjana	Bokth
	Elise	Pabriaga
	Caroline	Francia
Basingstoke and North Hampshire Hospital	Rebecca	Saich
	Hayley	Cousins
	Wendy	Fraser
	Rachel	Thomas

Supplementary Appendix for 'Anti-SARS-CoV2 antibody responses are impaired in patients with inflammatory bowel disease treated with infliximab'

	Matthew	Brown
	Benjamin	White
Birmingham Women's and Children's NHS Foundation Trust	Rafeeq	Muhammed
	Rehana	Bi
	Catherine	Cotter
	Jayne	Grove
	Kate	Hong
	Ruth	Howman
	Monica	Mitchell
	Sugrah	Sultan
	Bolton NHS Foundation Trust	Salil
Chris		Dawe
Robert		Hull
Natalie		Silva
Borders General Hospital	Jonathan	Manning
	Lauren	Finlayson
Calderdale and Huddersfield NHS Foundation Trust	Sunil	Sonwalkar
	Naomi	Chambers
	Andrew	Haigh
	Lear	Matapure
Cambridge University Hospitals NHS Foundation Trust	Tim	Raine
	Varun	George
	Christina	Kapizioni
	Konstantina	Strongili
	Tina	Thompson
Chelsea and Westminster Hospital NHS Foundation Trust	Philip	Hendy
	Rhian	Bull

Supplementary Appendix for 'Anti-SARS-CoV2 antibody responses are impaired in patients with inflammatory bowel disease treated with infliximab'

	Patricia	Costa
	Lisa	Davey
	Hayley	Hannington
	Kribashnie	Nundlall
	Catarina	Martins
	Laura	Avanzi
	Jaime	Carungcong
	Sabrina	Barr
Chesterfield Royal Hospital	Kath	Phillis
	Rachel	Gascoyne
Countess Of Chester Hospital NHS Foundation Trust	Ian	London
	Jenny	Grounds
	Emmeline	Martin
	Susie	Pajak
Darlington Memorial Hospital	Anjan	Dhar
	Ellen	Brown
	Amanda	Cowton
	Kimberley	Stamp
Dartford and Gravesham NHS Trust	Ben	Warner
	Carmel	Stuart
	Louise	Lacey
The Dudley Group NHS Foundation Trust	Shanika	de Silva
	Clare	Allcock
	Philip	Harvey
East and North Hertfordshire NHS Trust	Johanne	Brooks
	Pearl	Baker
	Hannah	Beadle

Supplementary Appendix for 'Anti-SARS-CoV2 antibody responses are impaired in patients with inflammatory bowel disease treated with infliximab'

	Carina	Cruz
	Debbie	Potter
East Lancashire Hospitals NHS Trust	Joe	Collum
	Farzana	Masters
East Suffolk and North Essex NHS Foundation Trust	Achuth	Shenoy
	Alison	O'Kelly
Glangwili Hospital	Aashish	Kumar
	Samantha	Coetzee
	Mihaela	Peiu
Great Ormond Street Hospital	Edward	Gaynor
	Sibongile	Chadokufa
	Bonita	Huggett
	Hamza	Meghari
	Sara	El-Khouly
	Fevronia	Kiparissi
	Waffa	Girshab
Great Western Hospitals NHS Foundation Trust	Andrew	Claridge
	Emily	Fowler
	Laura	McCafferty
Guy's and St Thomas' NHS Foundation Trust	Peter	Irving
	Karolina	Christodoulides
	Angela	Clifford
	Patrick	Dawson
	Sailish	Honap
	Samuel	Lim
	Raphael	Luber
	Karina	Mahiouz

Supplementary Appendix for 'Anti-SARS-CoV2 antibody responses are impaired in patients with inflammatory bowel disease treated with infliximab'

	Susanna	Meade
	Parizade	Raymode
	Rebecca	Reynolds
	Anna	Stanton
	Sherill	Tripoli
	Naomi	Hare
The Hillingdon Hospitals NHS Foundation Trust	Yih Harn	Siaw
	Lane	Manzano
	Jonathan	Segal
	Ibrahim	Al-Bakir
	Imran	Khakoo
Homerton University Hospital Foundation Trust	Nora	Thoua
	Katherine	Davidson
	Jagrul	Miah
	Alex	Hall
Hull University Teaching Hospitals NHS Trust	Shaji	Sebastian
	Melony	Hayes
	Sally	Myers
	Alison	Talbot
	Jack	Turnbull
	Emma	Whitehead
	Katie	Stamp
	Alison	Pattinson
	Verghese	Mathew
	Leanne	Sherris
Imperial College Healthcare NHS Trust	Lucy	Hicks
	Tara-Marie	Byrne

Supplementary Appendix for 'Anti-SARS-CoV2 antibody responses are impaired in patients with inflammatory bowel disease treated with infliximab'

	Leilani	Cabreros
	Hannah	Downing-Wood
	Sophie	Hunter
	Mohammad Aamir	Saifuddin
	Hemanth	Prabhudev
	Sharmili	Balarajah
James Paget University Hospitals NHS Foundation Trust	Helen	Sutherland
Kettering General Hospital	Ajay M	Verma
	Juliemol	Sebastian
	Mohammad Farhad	Peerally
King's College Hospital NHS Foundation Trust	Alexandra	Kent
	Lee Meng	Choong
	Benedetta	Pantaloni
	Pantelis	Ravdas
King's College Hospital NHS Foundation Trust (paediatric)	Babu	Vadamalayan
King's Mill Hospital	Stephen	Foley
	Becky	Arnold
	Cheryl	Heeley
	Wayne	Lovegrove
Liverpool University Hospitals NHS Foundation Trust	Philip J	Smith
	Giovanna	Bretland
	Sarah	King
	Martina	Lofthouse
	Lindsey	Rigby
	Sreedhar	Subramanian
	David	Tyrer

Supplementary Appendix for 'Anti-SARS-CoV2 antibody responses are impaired in patients with inflammatory bowel disease treated with infliximab'

	Kate	Martin
	Christopher	Probert
London North West University Healthcare NHS Trust	Nikolaos	Kamperidis
	Temi	Adedoyin
	Manisha	Baden
	Jeannette	Brown
	Feba	Chacko
	Michela	Cicchetti
	Mohammad	Saifuddin
	Priya	Yesupatham
Maidstone and Tunbridge Wells NHS Trust	Rohit	Gowda
	Maureen	Williams
Manchester University NHS Foundation Trust	Karen	Kemp
	Rima	Akhand
	Glaxy	Gray
	Anu	John
	Maya	John
	Diamond	Sathe
	Jennifer	Soren
The Mid Yorkshire Hospitals NHS Trust	Michael	Sprakes
	Julie	Burton
	Patricia	Kane
	Stephanie	Lupton
Milton Keynes University Hospital	George	MacFaul
	Diane	Scaletta
	Loria	Siamia
Newcastle Hospitals NHS	Chris	Lamb

Supplementary Appendix for 'Anti-SARS-CoV2 antibody responses are impaired in patients with inflammatory bowel disease treated with infliximab'

Foundation Trust	Mary	Doona
	Ashleigh	Hogg
	Lesley	Jeffrey
	Andrew	King
	R Alexander	Speight
Ninewells Hospital & Medical School	Craig	Mowat
	Debbie	Rice
	Susan	MacFarlane
	Anne	MacLeod
	Samera	Mohammed
Norfolk and Norwich University Hospitals NHS Foundation Trust	Mary	Anne Morris
	Louise	Coke
	Grace	Hindle
	Eirini	Kolokouri
	Catherine	Wright
North Bristol NHS Trust	Melanie	Lockett
	Charlotte	Cranfield
	Louise	Jennings
	Ankur	Srivastava
	Lana	Ward
	Nouf	Jeynes
North Tyneside General Hospital	Praveen	Rajasekhar
	Lisa	Gallagher
	Linda	Patterson
	Jill	Ward
	Rae	Basnett
	Judy	Murphy

Supplementary Appendix for 'Anti-SARS-CoV2 antibody responses are impaired in patients with inflammatory bowel disease treated with infliximab'

	Lauren	Parking
	Emma	Lawson
Nottingham University Hospitals NHS Trust	David	Devadason
	Gordon	Moran
	Neelam	Khan
	Lauren	Tarr
The Pennine Acute Hospitals NHS Trust	Jimmy	Limdi
	Kay	Goulden
	Asad	Javed
	Lauren	McKenzie
Portsmouth Hospitals NHS Trust	Pradeep	Bhandari
	Michelle	Baker-Moffatt
	Joanne	Dash
The Queen Elizabeth Hospital Kings Lynn NHS Trust	Alan	Wiles
	Hannah	Bloxham
	Jose	Dias
	Ellie	Graham
Queen Elizabeth University Hospital, Glasgow	Jonathan	Macdonald
	Shona	Finan
	Faye	McMeeken
	Stephanie	Shields
	John Paul	Seenan
Royal Berkshire NHS Foundation Trust	Des	DeSilva
	Ofori	Boateng
	Holly	Lawrence
	Susanna	Malkakorpi
The Royal Bournemouth and	Simon	Whiteoak

Supplementary Appendix for 'Anti-SARS-CoV2 antibody responses are impaired in patients with inflammatory bowel disease treated with infliximab'

Christchurch Hospitals NHS Foundation Trust	Kelli	Edger-Earley
Royal Cornwall Hospitals NHS Trust	Sarah	Ingram
	Sharon	Botfield
	Fiona	Hammonds
	Clare	James
Royal Devon and Exeter NHS Foundation Trust	Tariq	Ahmad
	Gemma	Aspinall
	Sarah	Hawkins
	Suzie	Marriott
	Clare	Redstone
	Halina	Windak
Royal Free London NHS Foundation Trust	Charles	Murray
	Cynthia	Diaba
	Fexy	Joseph
	Glykeria	Pakou
Royal Glamorgan Hospital	James	Berrill
	Natalie	Stroud
	Carla	Pothecary
	Lisa	Roche
	Keri	Turner
	Lisa	Deering
	Lynda	Israel
Royal Gwent Hospital	Evelyn	Baker
	Sean	Cutler
	Rina	Mardania Evans
	Maxine	Nash

Supplementary Appendix for 'Anti-SARS-CoV2 antibody responses are impaired in patients with inflammatory bowel disease treated with infliximab'

Royal Hampshire County Hospital	John	Gordon
	Emma	Levell
	Silvia	Zagalo
Royal Hospital for Sick Children, Edinburgh	Richard	Russell
	Paul	Henderson
	Margaret	Millar
Royal Manchester Children's Hospital	Andrew	Fagbemi
	Felicia	Jennings
	Imelda	Mayor
	Jill	Wilson
Royal Surrey County Hospital	Christopher	Alexakis
	Natalia	Michalak
Royal United Hospitals Bath	John	Saunders
	Helen	Burton
	Vanessa	Cambridge
	Tonia	Clark
	Charlotte	Ekblad
	Sarah	Hierons
	Joyce	Katebe
	Emma	Saunbury
	Rachel	Perry
The Royal Wolverhampton NHS Trust	Matthew	Brookes
	Kathryn	Davies
	Marie	Green
	Ann	Plumbe
Salford Royal NHS Foundation Trust	Clare	Ormerod
	Helen	Christensen

Supplementary Appendix for 'Anti-SARS-CoV2 antibody responses are impaired in patients with inflammatory bowel disease treated with infliximab'

	Anne	Keen
	Jonathan	Ogor
Salisbury District Hospital	Alpha	Anthony
	Emily	Newitt
Sandwell and West Birmingham NHS Trust	Edward	Fogden
	Kalisha	Russell
Sheffield Teaching Hospitals NHS Foundation Trust	Anne	Phillips
	Muaad	Abdulla
Shrewsbury and Telford Hospital NHS Trust	Jeff	Butterworth
	Colene	Adams
	Elizabeth	Buckingham
	Danielle	Childs
	Alison	Magness
	Jo	Stickleby
Singleton Hospital	Caradog	Thomas
	Elaine	Brinkworth
	Lynda	Connor
	Amanda	Cook
	Tabitha	Rees
Somerset NHS Foundation Trust	Emma	Wesley
	Alison	Moss
South Tees Hospitals NHS Foundation Trust	Arvind	Ramadas
	Julie	Tregonning
Southend University Hospital NHS Foundation Trust	Ioannis	Koumoutsos
	Viji	George
	Swapna	Kunhunny
	Sophie	Laverick

Supplementary Appendix for 'Anti-SARS-CoV2 antibody responses are impaired in patients with inflammatory bowel disease treated with infliximab'

St George's University Hospitals NHS Foundation Trust	Kamal	Patel
	Mariam	Ali
	Hilda	Mhandu
	Aleem	Rana
	Katherine	Spears
	Joana	Teixeira
	Richard	Pollok
	Mark	Mencias
	Abigail	Seaward
St George's University Hospitals NHS Foundation Trust (paediatric)	Nicholas	Reps
	Rebecca	Martin
St James's University Hospital	Christian	Selinger
	Jenelyn	Carbonell
	Felicia	Onovira
	Doris	Quartey
Stockport NHS Foundation Trust	Zahid	Mahmood
	Racheal	Campbell
	Liane	Marsh
Surrey and Sussex Healthcare NHS Trust	Monira	Rahman
	Sarah	Davies
	Ruth	Habibi
	Ellen	Jessup-Dunton
	Teishel	Joefield
	Reina	Layug
Tameside and Glossop Integrated Care NHS Foundation Trust	Vinod	Patel
	Joanne	Vere
Torbay and South Devon NHS	Gareth	Walker

Supplementary Appendix for 'Anti-SARS-CoV2 antibody responses are impaired in patients with inflammatory bowel disease treated with infliximab'

Foundation Trust	Stacey	Atkins
	Jasmine	Growdon
	Charlotte	McNeill
University Hospitals Birmingham NHS Foundation Trust	Rachel	Cooney
	Lillie	Bennett
	Louise	Bowlas
	Sharafaath	Shariff
University Hospitals Bristol NHS Foundation Trust	Aileen	Fraser
	Katherine	Belfield
University Hospitals of Derby and Burton NHS Foundation Trust	Said	Din
	Catherine	Addleton
	Marie	Appleby
	Johanna	Brown
	Kathleen	Holding
University Hospitals of Leicester NHS Trust	John	deCaestecker
	Olivia	Watchorn
University Hospitals Plymouth NHS Trust	Chris	Hayward
	Susan	Inniss
	Lucy	Pritchard
United Lincolnshire Hospitals NHS Trust	Jervoise	Andreyev
	Caroline	Hayhurst
	Carol	Lockwood
	Lynn	Osborne
	Amanda	Roper
	Karen	Warner
	Julia	Hindle
University College London	Shameer	Mehta

Supplementary Appendix for 'Anti-SARS-CoV2 antibody responses are impaired in patients with inflammatory bowel disease treated with infliximab'

Hospitals NHS Foundation Trust	James	Bell
	William	Blad
	Lisa	Whitley
University Hospital Llandough	Durai	Dhamaraj
	Mark	Baker
University Hospital Southampton NHS Foundation Trust	Fraser	Cummings
	Clare	Harris
	Amy	Jones
	Liga	Krauze
	Sohail	Rahmany
	Audrey	Torokwa
University Hospital of Wales (paediatric)	Amar	Wahid
	Zoe	Morrison
West Hertfordshire Hospitals NHS Trust	Rakesh	Chaudhary
	Melanie	Claridge
	Chiara	Ellis
	Cheryl	Kemp
	Ogwa	Tobi
West Middlesex University Hospital	Emma	Johnston
	Metod	Oblak
	Richard	Appleby
West Suffolk NHS Foundation Trust	Marium	Asghar
Western General Hospital	Charlie	Lees
	Debbie	Alexander
	Kate	Covil
	Lauranne	Derikx

Supplementary Appendix for 'Anti-SARS-CoV2 antibody responses are impaired in patients with inflammatory bowel disease treated with infliximab'

	Sryros	Siakavellas
	Helen	Baxter
	Scott	Robertson
Withybush General Hospital	Kerrie	Johns
	Rachel	Hughes
	Janet	Phipps
	Abigail	Taylor
Yeovil District Hospital NHS Foundation Trust	Katie	Smith
	Linda	Howard
	Dianne	Wood
York Teaching Hospital NHS Foundation Trust	Ajay	Muddu
	Laura	Barman
	Janine	Mallinson
Ysbyty Gwynedd	Iona	Thomas
	Kelly	Andrews
	Caroline	Mulvaney Jones
	Julia	Roberts

Supplementary Appendix for 'Anti-SARS-CoV2 antibody responses are impaired in patients with inflammatory bowel disease treated with infliximab'

Supplementary Table S2: Baseline characteristics stratified by baseline characteristics after propensity matching by inflammatory bowel disease (IBD) subtype, immunomodulator use, cancer, age, active IBD and comorbidities


Variable		Positive	Negative	p
Positive serology to SARS-CoV-2	Positive	3.9% (67/1704)	6.2% (105/1707)	0.0037
	Negative	96.1% (1637/1704)	93.8% (1602/1707)	
Age (years)		41.7 (31.1 - 55.6)	41.4 (31.1 - 56.1)	0.91
Sex	Female	46.4% (791/1704)	50.2% (857/1707)	0.023
	Male	53.6% (913/1704)	49.7% (848/1707)	
	Intersex	0.0% (0/1704)	0.1% (1/1707)	
	Prefer not to say	0.0% (0/1704)	0.1% (1/1707)	
Ethnicity	White	88.6% (1510/1704)	88.1% (1504/1707)	0.99
	Asian	7.1% (121/1704)	7.4% (127/1707)	
	Mixed	2.3% (40/1704)	2.3% (39/1707)	
	Black	1.2% (21/1704)	1.3% (23/1707)	
	Other	0.7% (12/1704)	0.8% (14/1707)	
Diagnosis	Crohn's disease	43.4% (739/1704)	43.4% (740/1707)	1.0
	Ulcerative colitis	53.2% (907/1704)	53.3% (909/1707)	
	IBD-unclassified	3.4% (58/1704)	3.4% (58/1707)	
Duration of IBD (years)		8.0 (3.0 - 15.0)	9.0 (4.0 - 16.0)	0.0010
Age at IBD diagnosis (years)		29.8 (21.5 - 42.8)	29.0 (20.8 - 41.8)	0.29
Immunomodulators at recruitment		23.4% (399/1704)	23.5% (401/1707)	0.97
5-ASA at recruitment		32.4% (552/1704)	33.4% (570/1707)	0.54
Steroids in 2020		19.5% (333/1704)	21.7% (370/1707)	0.13
BMI		25.2 (22.1 - 28.6)	24.8 (21.9 - 28.4)	0.52
Heart disease		3.6% (61/1704)	3.3% (57/1707)	0.71
Diabetes		5.3% (91/1704)	5.7% (97/1707)	0.71
Lung disease		16.0% (272/1704)	16.0% (273/1707)	1.0
Kidney disease		1.2% (20/1704)	1.8% (30/1707)	0.20
Cancer		0.5% (8/1704)	0.5% (8/1707)	1.0
Smoker	Yes	11.5% (196/1704)	10.3% (175/1707)	0.48
	Not currently	32.2% (549/1704)	32.3% (551/1707)	
	Never	56.3% (959/1704)	57.5% (981/1707)	
Meets clinical criteria for suspected or probable COVID-19		9.4% (161/1704)	9.0% (154/1707)	0.68
Tested with PCR for SARS-CoV-2		37.9% (645/1704)	38.4% (656/1707)	0.75
Positive PCR for SARS-CoV-2		5.6% (37/645)	4.8% (31/656)	0.46
Positive PCR for SARS-CoV-2 at least 2 weeks prior to serum sample		5.6% (33/586)	4.8% (29/610)	0.52
Hospitalised for confirmed COVID-19		0.4% (6/1704)	0.2% (4/1707)	0.55
Shielding behaviour Apr-Jul	I remained in my house or garden	32.3% (550/1704)	34.2% (583/1706)	0.20
	I only left the house for exercise on my own or with members of my household	38.8% (661/1704)	40.2% (686/1706)	
	I encountered people from outside of my household but <i>maintained social distancing</i>	26.6% (454/1704)	23.6% (403/1706)	
	I encountered people from outside of my household but <i>did not maintain social distancing</i>	2.3% (39/1704)	2.0% (34/1706)	
Exposure to documented cases of COVID-19		11.5% (196/1703)	11.0% (188/1707)	0.66
PHQ8		4.0 (1.0 - 9.0)	5.0 (1.0 - 9.0)	0.035
GAD7		3.0 (0.0 - 7.0)	3.0 (0.0 - 7.0)	0.17
Income deprivation score		0.1 (0.1 - 0.2)	0.1 (0.1 - 0.2)	0.049
Active disease (PRO2)		10.9% (185/1704)	10.4% (178/1707)	0.70
IBD Control 8		13.0 (9.0 - 16.0)	13.0 (9.0 - 16.0)	0.40
IBD Control VAS		79.0 (63.8 - 92.0)	79.0 (62.0 - 92.0)	0.21

Values shown are medians (interquartile range) and percentages (proportions) as appropriate.

Abbreviations: IBD = inflammatory bowel disease, 5-ASA = aminosalicylates, BMI = Body Mass Index, COVID-19 = coronavirus, PCR = polymerase chain reaction, SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2, PHQ8 = Patient Health Questionnaire depression scale, GAD7 = General Anxiety Disorder assessment, PRO2 = Patient Reported Outcome, VAS = Visual Analogue Scale


Supplementary Appendix for 'Anti-SARS-CoV2 antibody responses are impaired in patients with inflammatory bowel disease treated with infliximab'

Supplementary Figure S1: Regional seroprevalence of SARS-CoV-2 by NUTS1 region




Abbreviations: SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2, NUTS = Nomenclature of territorial units for statistic

Supplementary Appendix for 'Anti-SARS-CoV2 antibody responses are impaired in patients with inflammatory bowel disease treated with infliximab'
Supplementary Figure S2: Magnitude of antibody reactivity to SARS-CoV-2 in participants who had a positive PCR to SARS-CoV-2 at least two weeks earlier and positive anti-SARS-CoV-2 serology (≥ 1 COI), stratified by choice of biologic



Abbreviations: PCR = polymerase chain reaction, SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2, COI = Cut-Off Index

Supplementary Appendix for 'Anti-SARS-CoV2 antibody responses are impaired in patients with inflammatory bowel disease treated with infliximab'
Supplementary Figure S3: Magnitude of antibody reactivity to SARS-CoV-2 in participants treated with infliximab who had a positive PCR to SARS-CoV-2 at least two weeks earlier, stratified by immunomodulator use



Abbreviations: SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2, COI = Cut-Off Index; PCR = polymerase chain reaction